Track Achilles Therapeutics plc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Achilles Therapeutics plc ACHL · Stock Open Achilles Therapeutics plc in new tab

1.48 USD
Add to portfolio
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Achilles Therapeutics plc (ACHL)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Achilles Therapeutics plc Logo Achilles Therapeutics plc Analysis (ACHL)

United Kingdom Health Care Official Website Stock

Is Achilles Therapeutics plc a good investment? Achilles Therapeutics plc (ACHL) is currently trading at 1.48 USD.

Investor FAQ

Does Achilles Therapeutics plc pay a dividend?

No, it does not currently pay a dividend.

What asset class is Achilles Therapeutics plc?

Achilles Therapeutics plc is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

Company Profile

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Exchange Ticker
MUN (Germany) 698.MU
NMS (United States) ACHL
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion